Primary ovarian cancer cells are sensitive to the proaptotic effects of proteasome inhibitors

International Journal of Oncology

Volumn 36, Issue 3, 2010, Pages 707-713

  Pasquini, Luca ^a   Petronelli, Alessia ^a   Petrucci, Eleonora ^a   Saulle, Ernestina ^a   Mariani, Gualtiero ^a   Scambia, Giovanni ^b   Benedetti Panici, Pierluigi ^c   Greggi, Stefano ^d   Cognetti, Francesco ^e   Testa, Ugo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d National Cancer Institute   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Ovarian cancer; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; CISPLATIN; LEXATUMUMAB; MAPATUMUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PROTEASOME INHIBITOR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; ENZYME INHIBITOR; PYRAZINE DERIVATIVE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; CANCER CELL; CELL DEATH; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ADOLESCENT; ADULT; AGED; APOPTOSIS; DRUG RESISTANCE; FEMALE; METABOLISM; MIDDLE AGED; OVARIAN NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEASOME INHIBITORS; PYRAZINES; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77149165728     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000546     Document Type: Article

References (33)

1. Cannistra SA: Cancer of the ovary. N Engl J Med 351: 2519-2529, 2004.
2. Goldberg AL, Stein R and Adams J: New insights into proteasome function: from archaebacteria to drug development. Chem Biol 2: 503-508, 1995.
3. Palombella VJ, Rando OJ, Goldberg AL and Maniatis T: The ubiquitin-proteasome pathway is required for processing of the NF-κB1 precursor protein and the activation of NF-κB. Cell 78: 773-785, 2000.
4. Wong CY, Mayo MW and Balwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κappaB. Science 274: 784-787, 1996.
5. Lashinger LM, Zhu K, Willimas SA, Shrader M, Dinney CP and McConkey DJ: Bortezomib abolishes tumor necrosis factorrelated apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 65: 4902-4908, 2005.
6. Frankel A, Man S, Elliott P, Adams J and Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the protesome inhibitor PS-341. Clin Cancer Res 6: 3719-3728, 2000.
7. Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ and Fang B: Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 24: 4993-4999, 2005.
8. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, Ferretti G, Scambia G, Benedetti-Panici PL, Cognetti F, Humphreys R, Peschle C and Testa U: Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 12: 635-655, 2007.
9. Bazzaro M, Lee MK, Zoso A, Stirling W, Santillan A, Shih IeM and Roden RB: Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 66: 3754-3763, 2006.
10. Aghjanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J and Spriggs DR: Phase I trial bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 23: 5943-5949, 2005.
11. Ramirez PT, Landen CN Jr, Coleman RL, Milam MR, Levenback C, Johnston TA and Gershenson DM: Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer. Gynecol Oncol 108: 68-71, 2008.
12. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D and Gianni L: Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumors. Eur J Cancer 44: 1829-1834, 2008.
13. Ashkenazi A: Targeting death and decoy receptors of the tumornecrosis factor superfamily. Nat Rev Cancer 2: 420-431, 2002.
14. Bouralexis S, Findley DM and Evdokiou A: Death to the bad guys: targeting cancer via Apo2L/TRAIL. Apoptosis 10: 35-51, 2005.
15. Kimberley FC and Sereaton GR: Following a TRAIL: update on a ligand and its five receptors. Cell Res 14: 359-372, 2004.
16. Duiker EW, Mom CH, de Jong S, et al: The clinical trial of TRAIL. Eur J Cancer 42: 2233-2240, 2006.
17. Meng XW, Lee SH and Kaufmann SH: Apoptosis in the treatment of cancer: a promise kept? Curr Opin Cell Biol 18: 668-676, 2006.
18. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces death in multiple tumor types in vitro and in vivo. Br J Cancer 92: 1430-1441, 2005.
19. Pasquini L, Petrucci E, Riccioni R, Petronelli A and Testa U: Sensitivity and resistance of human cancer cells to TRAIL: mechanisms and therapeutical perspectives. Cancer Ther 4: 47-72, 2006.
20. Kern DH and Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay utilizing suprapharmacological drug exposures. J Natl Cancer Inst 82: 582-588, 1990.
21. Frehauf JP and Manetta A: Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression. Contrib Gynecol Ostet 19: 39-52, 1994.
22. Hollaway RW, Mehta RS, Finkler NJ, Li KT, McLaren CE, Parker RJ and Fruehauf JP: Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecol Oncol 87: 8-16, 2002.
23. Peter ME and Krammer PH: The CD95 (APO-1/Fas) DISC and beyond. Cell Death Diff 10: 26-35, 2003.
24. Boatright KM, Renatus M, Scott FL, et al: A unified model for apical caspases activation. Mol Cell 11: 529-541, 2003.
25. Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N and Anderson KC: Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther 8: 1053-1072, 2008.
26. Teicher BA: Newer cytotoxic agents: attacking cancer broadly. Clin Cancer Res 14: 1610-1617, 2008.
27. Orlowski RZ and Kuhn DJ: Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657, 2008.
28. Bruning A, Burger P, Vogel M, Rahmeh M, Friese K, Lehard M and Burges A: Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs (In press).
29. Woods DC, Liu HK, Nishi Y, Yanase T and Johnson AL: Inhibition of proteasome activity sensitizes human granulose tumor cells to TRAIL-induced cell death. Cancer Lett 260: 20-27, 2008.
30. Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ and Sayers TJ: Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J Natl Cancer Inst 100: 649-662, 2008.
31. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, Iacobucci A, MacLean M, Lo L, Fox NL and Oza AM: A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 14: 3450-3455, 2008.
32. Plummer R, Attard G, Pacey S, Li L, et al: Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancer. Clin Cancer Res 13: 6187-6194, 2007.
33. Ashkenazi A, Holland P and Eckardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 26: 3621-3630, 2008. 34. Ganten TM, Koschny R, Haas TL, et al: Proteasome inhibition sensitizes hepatoma carcinoma cells, but not human hepatocytes, to TRAIL. Hepatology 42: 588-597, 2005